Trump's tariffs could squeeze US factories and boost costs by up to 4.5%, a new analysis finds
By JOSH BOAK and PAUL WISEMAN
As President Donald Trump prepares to announce new tariff increases, the costs of his policies are starting to come into focus for a domestic manufacturing sector that depends on global supply chains, with a new analysis suggesting factory costs could increase by roughly 2% to 4.5%.
'There's going to be a cash squeeze for a lot of these firms,' said Chris Bangert-Drowns, the researcher at the Washington Center for Equitable Growth who conducted the analysis. Those seemingly small changes at factories with slim profit margins, Bangert-Drowns said, 'could lead to stagnation of wages, if not layoffs and closures of plants" if the costs are untenable.
The analysis, released Tuesday, points to the challenges Trump might face in trying to sell his tariffs to the public as a broader political and economic win and not just as evidence his negotiating style gets other nations to back down. The success of Trump's policies ultimately depends on whether everyday Americans become wealthier and factory towns experience revivals, a goal outside economists say his Republican administration is unlikely to meet with tariffs.
Trump has announced new frameworks with the European Union, Japan, the Philippines, Indonesia and Britain that would each raise the import taxes charged by the United States. He's prepared to levy tariffs against goods from dozens of other countries starting on Friday in the stated range of 15% to 50%.
The U.S. stock market has shown relief the tariff rates aren't as high as Trump initially threatened in April and hope for a sense of stability going forward. Trump maintains the tariff revenues will whittle down the budget deficit and help whip up domestic factory jobs, all while playing down the risks of higher prices.
'We've wiped out inflation," Trump said last Friday before boarding Marine One while on his way to Scotland.
But there's the possibility of backlash in the form of higher prices and slower growth once tariffs flow more fully through the world economy.
A June survey by the Atlanta Federal Reserve suggested companies would on average pass half of their tariff costs onto U.S. consumers through higher prices. Labor Department data shows America lost 14,000 manufacturing jobs after Trump rolled out his April tariffs, putting a lot of pressure as to whether a rebound starts in the June employment report coming out Friday.
The Washington Center for Equitable Growth analysis shows how Trump's devotion to tariffs carries potential economic and political costs for his agenda. In the swing states of Michigan and Wisconsin, more than 1 in 5 jobs are in the critical sectors of manufacturing, construction, mining and oil drilling and maintenance that have high exposures to his import taxes.
The artificial intelligence sector Trump last week touted as the future of the economy is dependent on imports. More than 20% of the inputs for computer and electronics manufacturing are imported, so the tariffs could ultimately magnify a hefty multitrillion-dollar price tag for building out the technology in the U.S.
The White House argues American businesses will access new markets because of the trade frameworks, saying companies will ultimately benefit as a result.
'The 'Made in USA' label is set to resume its global dominance under President Trump,' White House spokesman Kush Desai said.
There are limits to the analysis. Trump's tariff rates have been a moving target, and the analysis looks only at additional costs, not how those costs will be absorbed among foreign producers, domestic manufacturers and consumers. Also, the legal basis of the tariffs as an 'emergency' act goes before a U.S. appeals court on Thursday.
Treasury Secretary Scott Bessent said in an interview last week on Fox Business Network's 'Kudlow" show countries were essentially accepting the tariffs to maintain access to the U.S. market. 'Everyone is willing to pay a toll,' he said.
But what Bessent didn't say is U.S. manufacturers are also paying much of that toll.
'We're getting squeezed from all sides,'' said Justin Johnson, president of Jordan Manufacturing Co. in Belding, Michigan, northeast of Grand Rapids. His grandfather founded the company in 1949.
The company, which makes parts used by Amazon warehouses, auto companies and aerospace firms, has seen the price of a key raw material — steel coil — rise 5% to 10% this year.
Trump has imposed 50% tariffs on imported steel and aluminum. Jordan Manufacturing doesn't buy foreign steel. But by crippling foreign competition, Trump's tariffs have allowed domestic U.S. steelmakers to hike prices.
Johnson doesn't blame them. 'There's no red-blooded capitalist who isn't going to raise his prices'' under those circumstances, he said.
The Trump White House insists inflation is not surfacing in the economy, issuing a report through the Council of Economic Advisers this month saying the price of imported goods fell between December of last year and this past May. 'These findings contradict claims that tariffs or tariff-fears would lead to an acceleration of inflation,' the report concludes.
Ernie Tedeschi, director of economics at the Budget Lab at Yale University, said that the more accurate measure would be to compare the trends in import prices with themselves in the past and that the CEA's own numbers show 'import prices have accelerated in recent months.'
The latest estimate from the Budget Lab at Yale is the tariffs would cause the average household to have $2,400 less than it would otherwise have.
Josh Smith, founder and president of Montana Knife Co., called himself a Trump voter but said he sees the tariffs on foreign steel and other goods as threatening his business.
For instance, Smith just ordered a $515,000 machine from Germany that grinds his knife blades to a sharp edge. Trump had imposed a 10% tax on products from the EU that is set to rise to 15% under the trade framework he announced Sunday. So Trump's tax on the machine comes to $77,250 — about enough for Smith to hire an entry-level worker.
Smith would happily buy the bevel-grinding machines from an American supplier. But there aren't any. 'There's only two companies in the world that make them, and they're both in Germany,'' Smith said.
Then there's imported steel, which Trump is taxing at 50%. Until this year, Montana Knife bought the powdered steel it needs from Crucible Industries in Syracuse, New York. But Crucible declared bankruptcy last December, and its assets were purchased by a Swedish firm, Erasteel, which moved production to Sweden.
Smith beat the tariffs by buying a year's worth of the steel in advance. But starting in 2026, the specialty steel he'll be importing from Sweden is set to be hit with a 50% duty.
'The average American is not sitting in the position I am, looking at the numbers I am and making the decisions each day, like, 'Hey, we cannot hire those extra few people because we might have to pay this tariff on this steel or this tariff on this grinder,''' he said. 'I want to buy more equipment and hire more people. That's what I want to do.'
© Copyright 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yomiuri Shimbun
2 minutes ago
- Yomiuri Shimbun
Inside Science Labs Trying to Survive in the Trump Era
WORCESTER, Mass. – Anastasia Khvorova is perched at the edge of a massive scientific opportunity. Her laboratory at the University of Massachusetts Chan Medical School deploys cutting-edge RNA biology with one aim: to solve diseases – the ones that rob people of their memories or endanger pregnant women. Lately, she sees peril all around her. In the hallway, she bumps into one world-class chemist, then another, whose salaries are supported by federal funding the Trump administration has proposed to drastically slash. Many are immigrants like herself, who can no longer be sure America is the best country in the world to do science – or that they are welcome. Khvorova built her career by thinking boldly, but if slowdowns and cuts to federal science funding continue, she'll be forced to winnow her ambitions. 'What is happening right now is absolutely suicidal,' said Khvorova, speaking softly in Russian-accented English. 'I will stop making drugs. I will reduce my lab from 30 people to five. I will stop training scientists.' With stunning speed, the Trump administration has over the past six months cut research dollars, terminated grants and hit the brakes on federal funding, destabilizing an 80-year-old partnership between the government and universities that has made the United States a scientific superpower. The policy twists may sound arcane, but to researchers, everything is at stake. Day-to-day, Khvorova's lab is bright and buzzing. Scientists are trying to develop cures for Huntington's disease or halt the muscle loss that comes with aging. Longer term? 'I have no clue,' Khvorova said. The Trump administration portrays its changes as a targeted correction. Officials say grants are being terminated because they touch on topics with which the administration disagrees, such as increasing diversity in science. Funding to specific universities has been frozen because they haven't protected Jewish students, according to the administration. Fundamental research, Trump officials vow, will thrive. 'The money that goes to basic and blue-sky science must be used for that purpose, not to feed the red tape that so often goes along with funded research,' Michael Kratsios, director of the White House Office of Science Technology and Policy, said in a speech at the National Academy of Sciences in May. In contrast, a recent report from the American Association for the Advancement of Science found that President Donald Trump's budget request for 2026 – including a 40 percent cut to the National Institutes of Health – would cut the nation's basic research portfolio by about a third. A new report from the Congressional Budget Office found that a 10 percent cut to the NIH budget would result in two fewer drugs invented per year, a gradual decline that would go into full effect in 30 years. The Trump administration's science agenda is getting pushback in courts, in Congress and at the state level, but the impacts are being felt in research institutions across the country. As of Aug. 1, the Chan Medical School had a $37 million shortfall in funding due to long delays at the National Institutes of Health. Khvorova is no stranger to doing science under challenging conditions. She trained at Moscow State University in the waning days of the Soviet Union, when there was sometimes no hot water, no reagents for experiments, no salaries. But even that has not prepared her for the abrupt policy swings that threaten the unique American research system. 'We are working on developing cures, which are not politically oriented,' Khvorova said. 'Democrats age, and Republicans age.' Disruptions will ripple over decades, since no one can predict what science breakthroughs in the lab will turn into world-changing innovations. Khvorova's work built off years of federally funded research into soil-dwelling microscopic roundworms that revealed short strands of RNA perform like symphony conductors, controlling the activity of genes and turning their volume down. Worcester, a gritty former mill city in Central Massachusetts, is home to two Nobel laureates and an RNA Therapeutics Institute that has spawned 12 start-ups. Alnylam Pharmaceuticals, a company based on the phenomenon originally discovered in roundworms in labs at Chan Medical School and the Carnegie Institution of Washington, has discovered six drugs now approved for diseases that include rare genetic conditions and high cholesterol. The company's market capitalization has soared to more than $50 billion, and it has 2,200 employees. Basic research 'is almost like the starter when you bake sourdough bread. You can't make the bread without it,' said John Maraganore, who led Alnylam for nearly two decades before he stepped down in 2021. 'Girls just wanna have (NIH) funding' In the labyrinthine, slightly cluttered labs at Chan Medical School, scientists tend to high-end instruments with geeky names like 'Dr. Oligo,' using them to synthesize strands of RNA aimed at treating fatal forms of dementia or diseases that cause muscles to waste away. Under sterile hoods, they grow millions of mouse liver cells for experiments. In a small room called the 'wormhole,' decorated with colorful worms hanging from the door jamb like icicles, Victor Ambros, a Nobel Prize-winning worm biologist, zooms in on mutant roundworms wriggling across a yellowish agar gel. Unlike Harvard University, which has had billions of dollars in funding choked off by the Trump administration, Chan hasn't been targeted. But it is not untouched. Like hundreds of other institutions across America, it has been thrown off stride day-to-day and week-to-week by the Trump administration's unprecedented efforts to downsize and reshape the agencies that support science. Uncertainty looms over nearly every experiment and conversation. Slogans, not scientific sketches, are scrawled on the frosted glass wall of one office: 'We want scientific data, not alternative facts!' 'Girls just wanna have (NIH) funding' 'Science Not Silence!' More than a dozen NIH grants, out of several hundred, have been terminated, though they are tangled up in lawsuits challenging the Trump administration's actions. About 200 employees have been laid off or furloughed, about 3 percent of the medical school's 6,500 employees. A hiring freeze has been in place since March. Graduate school offers to nearly 90 young biomedical scientists were rescinded, though 13 spots were salvaged for next year's class. 'We have this feeling of extreme uncertainty, in a context where, previously, we could depend upon a robust system, a merit-based system that was predictable for the right reasons – the best science will get funded,' said Ambros, who shared the Nobel in medicine last year. Jesse Lehman, a graduate student who focuses on understanding the speed and dynamics of immune defenses against pathogens, became hooked on science when he first felt the rush of discovering things no one else knew. There are no guarantees in this career – the contest for federal funding is exceptionally competitive. But what has fueled the system is its reliability. The federal government funds the best research, year after year, and scientists chase grants without worrying that the funder may lose interest in neuroscience or immunology and decide instead to buy a sports team. But now, federal funding may be there one moment and gone the next. 'I have this fear that the career that I've worked 10 years on developing just may not be viable,' Lehman said. – The 20-year path to success In textbooks, science is a steady march of progress. In the lab, it's an iterative process – filled with detours and dead ends that sometimes turn out to be surprises that push the field forward. In 2006, Chan biologist Craig Mello shared the Nobel Prize with Stanford University biologist Andrew Fire for the discovery of a phenomenon called RNA interference: Short double strands of RNA could silence genes. It is a profound biological mechanism shared not just by tiny worms, but by humans. Other scientists built on the work, capturing the interest of venture capitalists and pharma companies. Many human diseases are caused by errant genes. What if, instead of treating patients' symptoms, doctors could give their patients drugs that just shut off the problematic ones? More than a billion dollars flowed into start-ups, but biology turned out to be a bit more complicated. Investor ebullience evaporated. Alnylam, an RNAi company, began trading below the amount of cash it had on hand, meaning investors thought its stock was less valuable than the money it had in the bank. Years of science – including a lot of chemistry – eventually turned a profound biological mechanism into a new class of safe effective drugs. 'Sickness doesn't have political boundaries,' said Phillip Zamore, a co-founder of Alnylam and a professor of biomedical sciences. 'Everyone deserves a better treatment for their disease, and I just want to make that possible. And I can't do that if my lab, my university, my colleagues' ability to do science is destroyed.' In the past few years, several biotech companies have spun out of Chan, including Comanche Biopharma, which is focused on a treatment for preeclampsia – a complication of pregnancy – and Atalanta Therapeutics, which is searching for cures for neurodegenerative diseases. Khvorova, a co-founder of both companies, came to the United States with very little money in the mid-1990s, intending to check a box on her résumé and stay a year or two. Instead, she became a 'typical example of the American Dream,' as she puts it. She's an inventor named on nearly 250 patents. She just scooped up one of the most prestigious prizes in biomedical research, with a $2.7 million award. She should be on top of the world. But as she walked to her lab on a recent Tuesday, she gestured sadly at a collection of empty champagne bottles sitting high up above the cabinets in the lounge outside. Each bottle, she noted, is a trained graduate student – a reminder that most of next year's class was turned away.
Yomiuri Shimbun
2 minutes ago
- Yomiuri Shimbun
U.S. Escalates Human Rights Criticism of South Africa and Brazil
The Trump administration is significantly escalating U.S. government criticism of perceived foes in South Africa and Brazil as the State Department's political leadership reimagines America's role in documenting human rights abuses around the world, according to leaked draft documents reviewed by The Washington Post. The department's annual human rights reports, which are scheduled to be transmitted to Congress on Tuesday, according to a memo seen by The Post, are expected to target the South African government for its alleged mistreatment of White Afrikaner farmers and the Brazilian government for its alleged persecution of former president Jair Bolsonaro, an ally of President Donald Trump. Human rights advocates, foreign leaders and other critics of the Trump administration say its claims about both governments are exaggerated. Within the State Department, there is considerable unease, too, over how the writing of these and other country-specific human rights reports were shaped compared with past years, with some saying the process was unduly politicized. The Post also has reviewed leaked draft reports for El Salvador, Israel and Russia. Those documents eliminate previous descriptions of abuses, including government corruption, prisoner abuse and persecution of LGBTQ+ individuals. The State Department has declined to comment directly on the draft documents but last week issued a broad defense of the administration's shift in priorities. 'Governments around the world continue to use censorship, arbitrary or unlawful surveillance and restrictive laws against disfavored voices, often on political and religious grounds,' a senior State Department official, speaking on the condition of anonymity under the agency's rules, told reporters. 'We are committed to having frank conversations … with our allies, our partners and also our adversaries to promote freedom of expression around the world.' This official also noted that the forthcoming human rights reports had been restructured to remove redundancies and increase readability. Representatives of the South African and Brazilian embassies in Washington did not respond to requests for comment. Current and former State Department officials familiar with this year's human rights reports describe a divisive process with internal disputes over certain countries, including South Africa, resulting in a months-long publication delay as drafts begun during the Biden administration underwent substantial revision. Uzra Zeya, a top official for human rights at the State Department during the Biden administration who now leads the Human Rights First nonprofit, said that Secretary of State Marco Rubio was seeking to 'weaponize and distort human rights policy' in a way that rewards rights-abusing allies while targeting political opponents and critics. The report for South Africa focuses on what the Trump administration says is the 'land expropriation of Afrikaners and further abuses against racial minorities in the country,' the draft documents show. Trump has claimed the country's White minority faces a 'genocide,' though human rights groups, and even some Afrikaner groups, have resoundingly dismissed that as untrue. Trump lectured South African President Cyril Ramaphosa during a visit to the White House in May, with the U.S. president showing his visitor purported video evidence of what he claimed proved the persecution of Afrikaners. While Ramaphosa acknowledged there were problems with safety in some rural parts of his country, he forcefully rejected the idea that White South Africans were being singled out – and at least one of the images Trump showed during the tense meeting was later found to not show South Africa at all. That same month, the Trump administration welcomed to the United States about 60 White South Africans as refugees, making a rare exception to its broader halt to refugee resettlement programs for people fleeing war or facing persecution around the world. The U.S. has also cut aid to South Africa and is planning to boycott November's meeting of the Group of 20 industrialized countries to be held in Johannesburg. U.S. officials have complained not only of the treatment of White Afrikaners but also South Africa's support of legal cases against U.S. ally Israel at the International Court of Justice. The draft report includes a lengthy section on antisemitism in South Africa. According to two people with knowledge of the process, speaking on the condition of anonymity for fear of retribution, career State Department staff pushed back on some of the proposed language in the South Africa report. There were specific concerns, these people said, about use of the word 'genocide,' which carries significant legal implications for U.S. policy under domestic and international law. One person with knowledge of the process said the administration wanted not just to strip down the South Africa draft left by the prior administration but reshape it entirely, highlighting claims of persecution against Afrikaners despite doubts about their veracity. A Trump political appointee, Samuel Samson, led the draft's rewriting after Africa subject matter experts in the Bureau of Democracy, Human Rights, and Labor refused to continue their involvement, citing the inclusion of false and misleading information, this person said. Samson later visited South Africa in July to conduct research, according to local media reports. He did not immediately respond to a request for comment. In Brazil's draft report, the State Department accused the country's left-wing government of 'disproportionately suppressing the speech of supporters of former president Jair Bolsonaro,' who is accused of attempting to stay in power with a violent coup. Bolsonaro has denied the charge. The draft report specifically mentions Brazilian Supreme Court Justice Alexandre de Moraes, stating that he 'personally ordered the suspension of more than 100 user profiles on the social media platform X (formerly Twitter)' in a way that impacted Bolsonaro's supporters on the far right. The Trump administration expanded U.S. sanctions on Moraes last month, with Rubio alleging the judge had committed 'serious human rights abuse, including arbitrary detention involving flagrant denials of fair trial guarantees and violations of the freedom of expression.' Moraes has pledged to ignore the sanctions and continue his work. Bolsonaro and his allies have appealed to Trump for help as he faces a variety of charges related to the 2022 attempted coup, which occurred roughly two years after Trump's supporters, hoping to overturn his election defeat in 2020, carried out a violent assault on the U.S. Capitol. 'I always talked about the prosecutions that Trump suffered. If he wants to say something about me, he'll decide to speak,' Bolsonaro told The Post this year. Administration officials have defended the shift in U.S. human rights priorities, and it's not unusual for a new administration respond to different trends, such as perceived attacks on freedom of expression in Europe and other democracies. The State Department human rights reports are the most comprehensive on the subject compiled by any single body in the world, and they are widely used in both U.S. and international courts. In particular, they are often used in immigration court during hearings on asylum and deportations. Appearing in front of the Senate Foreign Relations Committee in May, Rubio clashed with Democratic lawmakers, who asked why the State Department had canceled long-standing refugee programs but started a new program that focused specifically on Afrikaners from South Africa. Rubio said that the South Africans who arrived in the United States 'thought they were persecuted' but acknowledged there were millions of others facing persecution around the world who would not be resettled as refugees in the U.S.
Yomiuri Shimbun
2 minutes ago
- Yomiuri Shimbun
Japan's Nikkei Stock Average Allies to Record High, SoftBank Surges
TOKYO, Aug 12 (Reuters) – Japan's Nikkei share gauge .N225 powered to an all-time high on Tuesday, swept up by sharp gains for tech stocks, as it caught up with peaks scaled earlier this year by other major global stock markets. The Nikkei 225 rose as much as 2.1% to 42,715.72 in early trade, exceeding the previous high of 42,426.77 set on July 11, 2024. In a roller-coaster ride in 2024, the Nikkei had exceeded a record that had stood since 1989 during Japan's bubble economy. Japan's broader Topix .TOPX gauge has been setting successive record highs since July 24 and also scored a new all-time high on Tuesday. The U.S. Standard & Poor's 500 .SPX and MSCI's broadest gauge of global equities .MIWD00000PUS have been charting new peaks since June. Steep gains by tech shares helped the Nikkei finally get over the line. SoftBank Group soared 6.7% after Reuters reported the conglomerate was selecting banks for a U.S. listing of its payments app operator PayPay. Semiconductor industry heavyweights Advantest 6857.T and Lasertec 6920.T jumped more than 5%. 'The Nikkei was not able to hit a record until today because chip-related shares and auto shares dragged the index,' said Takamasa Ikeda, senior portfolio manager at GCI Asset Management. 'The Nikkei could soon peak as technology shares that led the Wall Street's rally have slowed down.' Global equities tumbled after U.S. President Donald Trump's April 2 'Liberation Day' announcement of sweeping tariffs on imports from dozens of countries into the U.S. Shares have since more than recouped those losses as trade concerns abated and enthusiasm over artificial intelligence companies soared. Foreign money has been flooding into the Japanese market of late, but data from the Tokyo Stock Exchange last week indicated those flows may have peaked. Overseas investors turned net sellers of Japanese stocks and futures for the first time in 16 weeks in the period ending Aug. 1. They sold a net 342 billion yen ($2.31 billion) of shares and futures, a sharp reversal from net purchases of 1.26 trillion yen in the previous week.
